MedTrace Logo

Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.

NCT00355199 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 246

Last updated 2017-08-10

Study results available
· View outcomes & findings →

Summary

Multicentric randomized phase III study comparing high doses of chemotherapy with Rituximab followed by auto-transplant HPC versus CHOP plus Rituximab as first line therapy in high risk patients with DLBCL Non-Hodgkin's lymphomas.

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Rituximab-HDS

Rituximab-HDS

DRUG

Rituximab-CHOP

Rituximab-CHOP

Sponsors & Collaborators

  • Gruppo Italiano Terapie Innovative nei Linfomi

    lead OTHER

Principal Investigators

  • Sergio Cortelazzo, MD · Divisione di Ematologia - Ospedale Centrale di Bolzano - 39100 Bolzano Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00355199 on ClinicalTrials.gov